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Abstract Sphingolipid activator proteins (saposins A, B, C,
and D) are derived from a common precursor protein (pro-
saposin) and specifically activate in vivo degradation of gly-










) closely mimics the
human disease with an elevation of multiple glycolipids. The








 mice showed a chronic form
of globoid cell leukodystrophy, establishing the essential in
vivo role of saposin A as an activator for galactosylcerami-
dase to degrade galactosylceramide. Seminolipid, the princi-
pal glycolipid in spermatozoa, and its precursor/degradative
product, galactosylalkylacylglycerol (GalEAG), were analyzed
in the testis of the two mouse mutants by electrospray ioniza-
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150% of the normal level at the terminal stage. In con-

















 mice. These analytical findings on the
two saposin mutants may shed some light on the physiologi-
 
cal function of seminolipid and GalEAG.
 
—Tadano-Aritomi,
K., J. Matsuda, H. Fujimoto, K. Suzuki, and I. Ishizuka.
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Sphingolipid activator proteins (saposins A, B, C, and D)
are small heat-stable glycoproteins, which are derived from
a common precursor protein (prosaposin) (1). Prosaposin
is encoded by a single gene and proteolytically processed to
 
saposins A, B, C, and D. These four saposins are all homolo-
gous to each other, having six conserved cysteines and one
common glycosylation site. In lysosomes, the saposins acti-
vate hydrolysis of glycolipids by lysosomal hydrolases. In
spite of the structural similarities of the four saposins, their
activator functions are specific, with some overlaps, for indi-
vidual hydrolases. Human patients with mutations in the sa-
posin B and C domains show phenotypes of metachromatic
leukodystrophy and Gaucher disease, indicating that sa-
posins B and C are essential for in vivo degradation of





and glucosylceramide by arylsulfatase A and galactosylcer-
amidase, respectively (2, 3). There are reports suggestive of
saposin A being a galactosylceramidase activator (4, 5), and
saposin D being a ceramidase activator (6, 7). However, it
was unclear whether either saposin A or D is indispensable
for normal cellular function. Recently, a mouse model was
generated by introducing a mutation in the saposin A do-
main of the prosaposin gene (8). The clinical, biochemical,









that saposin A is an indispensable activator of galactosyl-
ceramidase to degrade GalCer in vivo.
In addition to its well-documented role in lysosomal
degradation of glycolipids, putative functions for secreted
prosaposin have been proposed, including functions as a
ganglioside binding/transport protein (9), a neurotrophic
factor (10), and possible roles in gonadal development
(11). The prosaposin gene may also code for the major
sulfated glycoprotein of the Sertoli cell, which is postu-
lated to be essential in the process of spermatogenesis
(12, 13). Two mutations are known in human patients that
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all four processed saposins with a severe and complex










tion of multiple glycolipids in multiple organs, which










-sulfate] is the prin-
cipal glycolipid in spermatozoa of mammals comprising,
for example, approximately 3% of total lipids and more
than 90% of total glycolipids in boar spermatozoa (17,
18). Seminolipid is synthesized by sulfation of its precur-









-sulfotransferase (CST, EC 2.8.2.11)
and is degraded to GalEAG by arylsulfatase A, the enzyme
missing in metachromatic leukodystrophy (19). GalEAG is
synthesized by galactosylation of alkylacylglycerol (EAG)
by UDP-galactose:ceramide galactosyltransferase (CGT,
EC 2.4.1.62) and is likely to be degraded by galactosylcer-
amidase, which is deficient in globoid cell leukodystrophy.
CGT- or CST-deficient mice manifest complete inhibition
of spermatogenesis before the first meiotic division, pro-
viding strong support for the view that seminolipid and/
or GalEAG are indispensable for spermatogenesis (20,
21). Genetic abnormalities in the prosaposin gene may
well also interfere with the metabolism and function of
these galactolipids in the testis. We have analyzed semino-

















 with a sensitive analytical
method using mass spectrometry in order to investigate
the effect of the saposin/prosaposin abnormalities on gly-





















 mice were originally gener-
ated through gene targeting technology as previously described (8,


























 mating were used as controls. Mice were killed by








C until lipid analysis. Simultaneously some testes were pro-

















mice were the F2 generation and the genetic background was still a
mixture of 129/SvJ and C57BL6/J. All animal protocols used in
these studies have been approved by the Internal Review Board of




Testes were dissected and fixed in Bouin’s solution overnight.





sections were stained for the periodic acid-Schiff reaction fol-
lowed by hematoxylin staining.
 
Lipid extraction and analysis
 


















 mice of 20 and 34 days were used. Testes obtained
from two to six mice of each age and genotype were pooled and
 
extracted with chloroform-methanol as described previously (20,
22). The total lipid extract was analyzed by two-dimensional TLC










OH (65:25:4; v/v/v) or chloroform-
methanol-acetone-acetic acid-water (8:2:4:2:1; v/v/v/v/v) for the
second direction. The bands were visualized with orcinol (hexose-
containing lipids), azure A (sulfolipids), or cupric acetate-phos-
phoric acid (phospholipids and other lipids), and determined by
densitometry (CS-9000; Shimadzu, Kyoto, Japan) (20, 22).
Identification of lipids was performed by negative-ion liquid
secondary ion mass spectrometry (LSIMS) on a Concept IH mass
spectrometer (Shimadzu/Kratos, Kyoto, Japan) (23). Lipid
bands on the TLC plate were transferred to a polyvinylidene di-
fluoride membrane (Clear Blot Membrane-P; ATTO, Tokyo, Ja-
pan) by iron-blotting (Far-Eastern blotting) (24). The band on
the membrane was excised and placed on a mass spectrometer
probe tip with triethanolamine as the matrix (22, 25).
 
Partial purification and determination of seminolipid and 
GalEAG by electrospray ionization mass spectrometry 
combined with high-performance liquid chromatography
 




2.3 mg) prepared from the testis (50
mg wet weight) of each group of mice were dissolved in 0.2 ml of
chloroform and chromatographed on a prepacked silica gel col-
umn (Bond Elut SI 1 ml/100 mg; Varian, Harbor City, CA). After
eluting nonpolar lipids (cholesterol, cholesterol ester, triacylglyc-
erol, etc.) with 0.5 ml each of chloroform and chloroform-metha-
nol (95:5; v/v), GalEAG and seminolipid were eluted with 0.5 ml
each of chloroform-methanol, (90:10) and (85:15), respectively.
The fractions were diluted with methanol (10–30 times for GalEAG




l portions were directly









column (Shiseido, Tokyo) using the HP 1100 HPLC system (Agi-
lent Technologies, Tokyo) (26) and eluted isocratically with metha-
nol or methanol-water (9:1) for the determination of GalEAG or
seminolipid, respectively, at 0.2 ml/min. Electrospray ionization
mass spectrometry (ESIMS) was carried out on the LCQ DECA ion
trap mass spectrometer (ThermoFinnigan, San Jose, CA) fitted
with an ESI probe. A deactivated coated glass capillary, 0.1 mm ID,





C, and the spray voltage set at 5.0 kV. The sheath gas and aux
gas flow rates were set to 70 and 20 in an arbitrary unit, respectively.
The tube lens offset was set at 0 V, which corresponds to the tube
lens voltage of 120 V. Low-energy collision-induced dissociation




) was carried out











 torr, and the relative collision energies used ranged
from 40 to 45%. Concentrations of seminolipid and GalEAG in the
samples were determined by ESIMS combined with high-perfor-
mance liquid chromatography (HPLC) (LC-ESIMS) in the nega-
tive or positive ion mode, respectively. Selected reaction monitor-






























 739 were monitored for seminolipid




). The trap was run with automatic














 mice initially grew normally and were indis-
tinguishable from their littermates. They developed slowly
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2.5 months and survived up to 5 months (8). Both males and
females were fertile, and they could produce several genera-
tions of pups beginning at around 60 days during their life-
time, indicating the nearly normal development of sper-








 mice. Histologically, no
obvious abnormality was recognized in the testis.








 mice died in utero,
and those that were born were thought to consist of two dis-
tinct clinical phenotypes, i.e., neonatally fatal and later on-
set. The former (more than 50% of live births) might die
within the first 24–48 h. The latter developed rapidly pro-
gressive severe neurological signs around 20 days and died
by 35–38 days (16). As the mutant line was backcrossed to
the C57BL6/J background, the proportion of live births
steadily declined. The line can now be considered geneti-








 mice die in
utero and live births are rare. Only the testes from the lat-
ter group were analyzed. Although it was impossible to









 mice was not decreased even at the ter-





























 3) were 51, 44, and 34
mg/testis, respectively. Histological examination showed
no obvious evidence of abnormal spermatogenesis at 30
days, although the number of the late spermatids might be
slightly reduced as compared with the normal littermates.
 
Determination of seminolipid and GalEAG by LC-ESIMS
 

























tively. These ions are consistent with the EAG molecular
species of 16:0 alcohol and 16:0 fatty acid. Other molecu-
lar species were observed at 28 Da higher, but their inten-




 795 and 739. In the




























 739) ions, elimination of
the acyl residue was predominant, as demonstrated by the




 539 and 483, respec-
tively (Fig. 1). Seminolipid and GalEAG in the samples,
which were eluted as a single peak at about 2.5 min, were




 539 and 483, re-
spectively, in the SRM mode. The calibration curves were












) of greater than 0.995. Because sem-
inolipid is the major glycolipid in the testis, it could be
determined using an aliquot of the total lipid extract with-
out further purification. On the other hand, partial purifi-
cation was a prerequisite for quantification of GalEAG, be-
cause it is a minor glycolipid, particularly in the testis of
normal adult mice. For both seminolipid and GalEAG,
complete purification is not necessary: the presence of
other glycolipids and/or phospholipids did not interfere





amounts of faster-eluting nonpolar lipids were removed
by the prepacked silica gel column. To examine the recov-
ery and the sample-to-sample variation of the method, the
known amounts of seminolipid and GalEAG were added
to the total lipid extract before passing through the col-




, partial purification by the col-
umn did not reduce the recovery of seminolipid or
GalEAG. The coefficients of variation of six separate ex-
periments were less than 3% and those of the recoveries
from four different samples, i.e., with or without addition
of the three known amounts of seminolipid and GalEAG,
were less than 9%. These results could confirm the reli-
ability of the method. The precision of the method was
further established by six separate determinations using
purified glycolipids as well as the crude fractions contain-
ing seminolipid and/or GalEAG. The coefficients of varia-
tion were 0.4–1.6%. The detection limits for seminolipid
and GalEAG were 10 and 50 pmol/ml, i.e., 0.02 and 0.1
pmol/injection, respectively, at a signal-to-noise ratio of 3.
 



















The putative bands on the TLC plates were identified
as seminolipid and GalEAG with 16:0 alcohol and 16:0
Fig. 1. Electrospray ionization mass spectrometry (ESIMS) spectra
of seminolipid and galactosylalkylacylglycerol (GalEAG). Semino-
lipid: negative-ion tandem mass spectrometry [MS/MS (MS2)] spec-
trum of [M  H] ion at m/z 795. GalEAG: positive-ion MS2 spectrum
of [M  Na] ion at m/z 739.
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fatty acid by iron-blotting followed by negative-ion LSIMS
(20). By visual examination of the two-dimensional TLC
plates (Fig. 2), the band corresponding to GalEAG (1 in
Fig. 2) was reduced in the testis of wild-type mice at 109
days and significantly increased in the testis of saposin
A/ mice at 141 days. The seminolipid band (2 in Fig. 2)
was slightly increased in the testis of prosaposin/ mice
at 34 days.
Age-related changes in the level of GalEAG and semino-
lipid were determined by the LC-ESIMS2 technique in the
testis of saposin A/ and prosaposin/ mice in compar-
ison with wild-type mice (Fig. 3). In the testis of wild-type
mice, the level of GalEAG dramatically increased by 12
days, then reached maximum at around 16 days, and de-
creased rapidly to the adult level. A similar pattern was ob-
served in the testis of prosaposin/ mice. In the testis of
saposin A/ mice, by contrast, the GalEAG level kept in-
creasing and reached 10 times as high as the normal level
at around 70 days after birth (Fig. 3A).
In the testes of wild-type and saposin A/ mice, the
seminolipid level increased rapidly by 12 days concomi-
tant with its precursor GalEAG, just before spermatocytes
normally begin to appear at the zygotene stage (20, 27).
The level of seminolipid then increased gradually by 17
days and remained almost constant until the terminal
stage. In contrast, the testis of prosaposin/ mice con-
tained 150% of the normal level of seminolipid at their
terminal stage of 34 days (Fig. 3B).
No significant changes in other lipids
except sphingomyelin
TLC profiles of polar glycolipids, including longer
chain neutral glycolipids and gangliosides, in the testis of
saposin A/ and prosaposin/ mice were essentially
similar as compared with age-matched littermates. No sig-
nificant changes were observed in the concentration of
major phospholipids, including phosphatidylethanola-
mine, phosphatidylcholine, phosphatidylserine, phospha-
tidylinositol, and cardiolipin (data not shown). The level
of sphingomyelin was 170% of the normal level in the
testis of prosaposin/ mice at the terminal stage of 34
days (1.4 mol/g wet tissue). The sphingomyelin levels in
the testes of other groups of mice, including 20-day-old
prosaposin/ mice, were within the range of 0.7–0.9
mol/g wet tissue.
DISCUSSION
The gene encoding prosaposin is unusual in several re-
spects (1). It encodes a precursor protein, prosaposin,
which eventually is processed in the lysosome to the four
homologous proteins, saposins A, B, C, and D. Existence
of human patients deficient in either saposin B or C (2, 3)
and an experimental mouse line deficient in saposin A (8)
clearly indicates the relatively specific nature of the in vivo
activating function of each of the saposins. On the other
hand, prosaposin itself is postulated to have a few physio-
logical functions, including as the Sertoli cell major sul-
TABLE 1. Recovery of seminolipid and GalEAG
Added (A)  Determined (D) Recovery (R)
Seminolipid GalEAG Seminolipid GalEAG Seminolipid GalEAG
nmol %
0 0 40.7 	 0.5a 11.6 	 0.8
1.8 0.9 42.5 	 0.5 12.5 	 1.0 103 	 8b 105 	 9c
5.4 2.7 46.1 	 0.6 14.3 	 1.4 99 	 4 98 	 6
16.2 8.1 56.6 	 0.9 19.6 	 2.1 98 	 3 99 	 5
GalEAG, galactosylalkylacylglycerol. The total lipid extract (2.3
mg) prepared from the testis (50 mg wet tissue) of saposin A/ mice
(118 days of age), which contained 40.7 nmol of seminolipid and 11.6
nmol of GalEAG, was mixed with the known amount (A) of purified
seminolipid and GalEAG. After passing through the prepacked silica
gel column, an aliquot of the fractions containing seminolipid or
GalEAG was determined by electrospray ionization mass spectrometry
(ESIMS) combined with high-performance liquid chromatography
(LC-ESIMS) as described in the text.
a Values are the mean 	 coefficient of variation (%) of six separate
experiments.
b Recovery (R) for seminolipid  [(D  40.7)/A]  100.
c R for GalEAG  [(D  11.6)/A]  100.
Fig. 2. Two-dimensional TLC of a total lipid extract from the tes-
tis of wild-type (25 and 109 days), prosaposin/ mice (34 days),
and saposin A/ mice (141 days). An aliquot of the total lipid ex-
tract corresponding to 2.5 mg of testis was separated on a TLC plate
with chloroform-methanol-water containing 0.2% CaCl2 (65:25:4;
v/v/v) for the first direction (1D), and chloroform-methanol-3
M NH4OH (65:25:4; v/v/v) for the second direction (2D). Gly-
colipid bands were visualized with the orcinol reagent. Identifica-
tion of components was performed by negative-ion liquid secondary
ion mass spectrometry after iron-blotting: 1, GalEAG; 2, semino-
lipid. Seminolipid from boar testis (lower band) and GalEAG (up-
per band) prepared by desulfation of seminolipid (18) were ap-
plied as references in upper and left sides in each plate.
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fated glycoprotein in the testis (12, 13). The precise physi-
ological function of the Sertoli cell major sulfated
glycoprotein is not known, but Morales et al. reported im-
paired spermatogenesis in a prosaposin-deficient mouse
at 37 days (28). These previous findings clarified many as-
pects of the physiological functions of prosaposin and sa-
posins. Nevertheless, many questions remain, particularly
with respect to the function of the gene products in the
testis. In this study, we report the results of our analytical
studies on the testis of prosaposin/ and saposin A/
mice. Particular attention was focused on the characteris-
tic lipid of the testis, seminolipid, and its metabolic pre-
cursor/degradative product, GalEAG. The former is de-
graded by arylsulfatase A, which is activated by saposin B
and the latter by GalCer activated by saposin A.
New methodologies or modifications of existing meth-
odologies needed to be developed first that would be suit-
able for analysis of the small amounts of glycolipids in
mouse testis. A variety of procedures were examined for
determining the sulfate ester content of various biomole-
cules, and some of them have been adopted for quantifi-
cation of sulfoglycolipids including seminolipid. We re-
cently adopted ion chromatography, that is, quantitation
of ionic substances by ion conductimetry after separation
by anion-exchange chromatography, for the determina-
tion of the sulfate liberated by hydrolysis of sulfolipids
(29). It has the advantage of increased precision for wide
concentration ranges and applicability to sulfolipids with
various structures, because determination is based on lib-
erated sulfate group using sodium or potassium sulfate as
the standard. However, the sensitivity is not adequate for
determination of minor components in the biological
samples or cultured cells. The present results showed that
the use of LC-ESIMS has a great advantage in sensitivity
and can be applied not only to sulfoglycolipids but also to
neutral glycolipids in the crude lipid extracts. By MS2 in
the SRM mode, the signal-to-noise ratio and the peak
shape were greatly improved as compared with those on
the selected ion monitoring chromatogram. Seminolipid
as well as its nonsulfated counterpart, GalEAG, in the
crude preparations could be determined specifically even
in the presence of other lipids. Although the linear range
for quantification is limited due to the characteristics of
the ion trap analyzer, the detection limit was less than 0.1
pmol/injection, which is 1,000 times lower than that of
the azure A method (30) or ion chromatography (29) for
sulfated lipids.
By using the LC-ESIMS2 technique, the age-related
changes of seminolipid and GalEAG levels were deter-
mined in the testis of saposin A/ and prosaposin/
mice (Fig. 3). The GalEAG level increased up to 10 times
the normal level in the testis of saposin A/ mice, con-
firming that saposin A is indispensable for in vivo degrada-
tion of GalEAG as well as GalCer (8). Unexpectedly, the
level of GalEAG decreased with age in the testis of
prosaposin/ mice, similar to that in the wild-type mice,
despite the fact that the prosaposin/ mouse is com-
pletely mRNA negative, i.e., no prosaposin, and conse-
quently, none of the individual saposins, including sa-
posin A, should be generated (16). Although we cannot
offer an explanation for this paradox, the observation is
firm and consistent with the much larger puzzle that pro-
saposin deficiency does not exhibit any of the phenotype
of globoid cell leukodystrophy (i.e., saposin A deficiency)
despite the absence of saposin A in the prosaposin/
mouse (8, 16).
In spite of the increased level of the precursor GalEAG,
the level of seminolipid was normal in the testis of saposin
A/ mice at all ages tested, suggesting that the activity of
CST, which sulfates GalEAG to seminolipid, is regulated to
maintain the seminolipid level within the normal range. In
contrast, the seminolipid level in the testis of prosaposin/
mice at 34 days was 150% of the normal level (Fig. 3B).
The result could suggest that saposin B activates in vivo
degradation of seminolipid as well as galactosylsulfatide
for several reasons: 1) While we could present only two
data points, these derived from pooled samples and repre-
sent averages of the pooled testis. Given the precision of
our analytical methodology, this ensures correct overall es-
timates, although it conversely obscures biological varia-
Fig. 3. Age-related changes of GalEAG and seminolipid levels in
the testis of saposin A/ and prosaposin/ mice in comparison
with wild-type mice. The fractions of individual glycolipids obtained
from the prepacked silica gel column were determined by electro-
spray ionization tandem mass spectrometry combined with high-
performance liquid chromatography as described in the text. Data
are expressed as the means of duplicate experiments.
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tions among individual testes. 2) The level of seminolipid
at 34 days is twice as high as that at 20 days in the testis of
prosaposin/ mice (Fig. 3B). This may suggest the accu-
mulation of seminolipid with age, although we could not
follow the age-related changes because of the exceedingly
rare live births and limited life span (35–38 days) of
prosaposin/ mice. 3) It is well established that saposin B
is an activator for arylsulfatase A, which is deficient in
metachromatic leukodystrophy, and that seminolipid is a
substrate of arylsulfatase A (19). 4) The seminolipid level
increases in the tissue of arylsulfatase A/ mice (Molan-
der-Melin, Månsson, Fredman, et al., personal communi-
cation). While these points provide only circumstantial
support, they are collectively consistent with saposin B de-
ficiency being the cause of seminolipid accumulation in
the testis of the prosaposin/ mouse.
These results indicated that testicular germ cells at the
leptotene-zygotene stage, when biosynthesis of GalEAG
and seminolipid begins, are not affected by lack of sa-
posins or prosaposin. Normal spermatogenesis in saposin
A/ mice would suggest that either 1) accumulation of
GalEAG, which should be restricted to lysosomes, may not
affect the process of spermatogenesis, or 2) when the sem-
inolipid level is kept within the normal range, spermato-
genesis is normal regardless of the GalEAG level, although
the arrested stage of spermatogenesis in CST-deficient
mice is somewhat later than that in CGT-deficient mice
(21).
Morales et al. (28) reported that 37-day-old prosaposin/
mice showed several abnormalities in their reproductive
organs, including testis, prostate, seminal vesicles, and
epididymis. They showed that smaller testes (30% reduc-
tion in weight) of prosaposin/ mice are associated with
reduced spermiogenesis, the late spermatids being partic-
ularly affected. In the present study, however, histological
analyses of the testis of saposin A/ mice showed that the
mutation at the saposin A domain in the prosaposin mole-
cule does not affect the process of spermatogenesis. Fur-
thermore, we did not observe any morphological defects
in the testis or obvious abnormality in spermiogenesis, at
least at 30 days of age in the prosaposin–/– mice lacking
prosaposin itself. Although the reason for the apparent
discrepancy between our findings and those of Morales et
al. (28) is not clear, our results would pose the question of
whether prosaposin, as the major sulfated glycoprotein of
the Sertoli cell, is indispensable for normal spermatogene-
sis. We have not been able to test the possibility that sper-
matogenesis in prosaposin/ mice is normal at 30 days
but reduced at 37 days, because of the exceedingly rare
live births of homozygous prosaposin/ mice ever since
the genetic background of the line was made homoge-
neous to the C57BL6/J strain. Even when homozygous
prosaposin/ mice are born, very few survive to 37 days.
Recently, a spermatogonial cell line, which can differenti-
ate into spermatocytes and spermatids in the presence of
stem cell factor, was created (31). It was reported that
sperm tails were not evident, although round spermatids
were generated in the absence of Sertoli cells. These re-
sults may suggest that prosaposin is indispensable only for
the final phase of spermatogenesis, which consists of a
morphological transformation of spermatids. Insofar as
the first wave of spermatogenesis is complete at 34 days in
mice, it might not be ruled out that spermatogenesis in
prosaposin/ mice is reduced at the final phase, which
could cause abnormalities in the testis at 37 days, as de-
scribed by Morales et al. (28).
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